<SEC-DOCUMENT>0001193125-14-268455.txt : 20140715
<SEC-HEADER>0001193125-14-268455.hdr.sgml : 20140715
<ACCEPTANCE-DATETIME>20140715075133
ACCESSION NUMBER:		0001193125-14-268455
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20140714
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140715
DATE AS OF CHANGE:		20140715

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPLIGEN CORP
		CENTRAL INDEX KEY:			0000730272
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				042729386
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14656
		FILM NUMBER:		14974663

	BUSINESS ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		7814499560

	MAIL ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d757843d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION&nbsp;13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): July&nbsp;14, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>REPLIGEN CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-14656</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>04-2729386</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>02453</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code (781)&nbsp;250-0111 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report.) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;15, 2014, Repligen Corporation (the &#147;Company&#148; or
&#147;Repligen&#148;) announced Jon K. Snodgres&#146; appointment as Chief Financial Officer of the Company, effective July&nbsp;14, 2014 (the &#147;Start Date&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jon Snodgres will be responsible for leading the Company&#146;s financial operations.&nbsp;Prior to joining the Company, Mr.&nbsp;Snodgres was
most recently CFO at Maquet Cardiovascular, a medical device company.&nbsp;Mr. Snodgres began his tenure as CFO at Maquet in 2009. He was previously the Vice President of Finance for the Laboratory Products Group at Thermo Fisher Scientific, a
position which he held for three years. Mr.&nbsp;Snodgres began his career in finance at AlliedSignal/Honeywell International. Mr.&nbsp;Snodgres holds a B.S.B.A. in finance from Northern Arizona University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with his employment, the Company entered into a letter agreement, dated June&nbsp;10, 2014 (the &#147;Employment
Agreement&#148;) which sets forth certain terms of Mr.&nbsp;Snodgres&#146; employment. There are no other arrangements or understandings between Mr.&nbsp;Snodgres and any other persons pursuant to which he was selected as the Company&#146;s Chief
Financial Officer. Additionally, there are no transactions involving the Company and Mr.&nbsp;Snodgres that the Company would be required to report pursuant to Item&nbsp;404(a) of Regulation S-K. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Employment Agreement, Mr.&nbsp;Snodgres will receive an annual base salary of $320,000 and he will be eligible to
receive an annual performance bonus under the Company&#146;s Executive Incentive Compensation Plan. The Company will target such bonus at up to 50% of Mr.&nbsp;Snodgres&#146;s annual base </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
salary; however, the actual bonus percentage is discretionary and will be subject to the Board of Directors&#146; assessment of Mr.&nbsp;Snodgres&#146;s performance as well as general business
conditions at the Company. For 2014, the target bonus will be prorated at 23.4%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Employment Agreement further provides that the Board
of Directors will grant Mr.&nbsp;Snodgres an incentive stock option to purchase 10,000 shares of the Company&#146;s common stock (the &#147;Option Grant&#148;) under the Company&#146;s Amended and Restated 2012 Stock Option and Incentive Plan (the
&#147;Plan&#148;). The Employment Agreement also provides that the Board of Directors will grant to Mr.&nbsp;Snodgres a restricted stock unit award for 5,000 shares of the Company&#146;s common stock (the &#147;RSU Award&#148;) under the Plan.
Twenty percent (20%)&nbsp;of each of the Option Grant and the RSU Award will vest and become exercisable on the first, second, third, fourth and fifth anniversaries of the respective date of grant. In addition, Mr.&nbsp;Snodgres will be eligible to
receive additional incentive equity awards under the Company&#146;s executive incentive plans or programs, with the target value of any such awards at an aggregate value of 50% of total target compensation. Mr.&nbsp;Snodgres will be also be eligible
to participate in all customary employee benefit plans or programs of the Company generally available to the Company&#146;s full-time employees and/or executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the Employment Agreement provides that Mr.&nbsp;Snodgres&#146; employment with the Company is at will and may be terminated by
either party at any time with or without notice and for any or no reason or cause. In the event Mr.&nbsp;Snodgres&#146; employment is terminated without cause, Mr.&nbsp;Snodgres will be entitled to receive severance pay equal to six months of his
base salary in effect as of the termination date (less required deductions and withholdings) to be paid in the form of salary continuation on the Company&#146;s standard payroll dates following the termination date, and fifty percent of his unvested
stock options and restricted stock unit awards will vest immediately. Mr.&nbsp;Snodgres will also receive a continuation of group health insurance coverage through COBRA for a period of six months with the cost of such benefits to be shared in the
same relative proportion by the Company and Mr.&nbsp;Snodgres as in effect on the date of termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the
Employment Agreement is qualified in its entirety by reference to the Employment Agreement, which is filed with this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01. Regulation FD Disclosure. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;15, 2014, the Company issued a press announcing Mr.&nbsp;Snodgres&#146; appointment as Chief Financial Officer of the Company. The
full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01.
Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.1
Letter Agreement, dated as of June&nbsp;10, 2014, by and between Repligen Corporation and Jon K. Snodgres. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">99.1 Press Release by Repligen Corporation,
dated July 15, 2014. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">REPLIGEN CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: July&nbsp;15, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Walter C. Herlihy</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Walter C. Herlihy</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:11.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter Agreement, dated as of June 10, 2014, by and between Repligen Corporation and Jon K. Snodgres.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release by Repligen Corporation, dated July 15, 2014.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d757843dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;10, 2014 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jon Snodgres </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">22 Crest Terrace </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Montville, NJ 07045 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Re: <U>Employment Agreement </U></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Jon: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter agreement (the &#147;Agreement&#148;) sets forth the terms of your employment with Repligen Corporation (the &#147;Company&#148;). This Agreement
supersedes any prior oral or written agreements or understandings related to the terms and conditions of your employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <B>Position</B>. Your
position with the Company will be Chief Financial Officer and you will report directly to the Chief Executive Officer of the Company (the &#147;CEO&#148;). This is a full-time position. While you render services to the Company, you will not engage
in any other employment, consulting or other business activity (whether full-time or part-time) without prior written approval from the CEO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <B>Start
Date</B>. Your employment will begin on July&nbsp;14, 2014, unless another date is mutually agreed upon by you and the Company. For purposes of this Agreement, the actual first day of your employment shall be referred to as the &#147;Start
Date.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <B>Salary</B>. The Company will pay you a salary at the rate of $320,000 per year (the &#147;Base Salary&#148;), payable in accordance
with the Company&#146;s standard payroll schedule and subject to applicable deductions and withholdings. Your salary will be subject to periodic review and adjustments at the Company&#146;s discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <B>Annual Bonus</B>. You will be eligible to receive an annual performance bonus under the Company&#146;s Executive Incentive Compensation Plan (or such
other applicable plan or program adopted by the Company) (the &#147;Bonus Plan&#148;). The Company will target the bonus at up to 50% of the Base Salary. For 2014, the target bonus will be prorated at approximately 23.4% based upon your commencing
employment on the date referred to in paragraph 2. The actual bonus percentage is discretionary and will be subject to the Company&#146;s assessment of your performance, as well as business conditions at the Company. The bonus also will be subject
to approval by and adjustment at the discretion of the Company&#146;s board of directors or compensation committee and the terms of the Bonus Plan; provided that you shall be eligible for a prorated bonus for 2014 based upon the number of days in
2014 that you work for the Company. The annual performance bonus, if any, shall be paid between January&nbsp;1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> and March&nbsp;15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the
calendar year following the applicable bonus year. You must be employed on the bonus payment date to earn any part of a bonus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <B>Stock Options and
Incentive Grants</B>. The Company shall grant you an incentive stock option to purchase 10,000 shares of the Company&#146;s Common Stock (the &#147;Option Grant&#148;) and a restricted stock unit award for 5,000 shares of the Company&#146;s Common
Stock (the &#147;RSU Grant&#148; and collectively with the Option Grant, the &#147;Equity Awards&#148;)) under the Company&#146;s Amended and Restated 2012 Stock Option and Incentive Plan (the &#147;Plan&#148;). The foregoing options shall be issued
at an exercise price equal to the fair market value of the Common Stock as determined by the Company&#146;s board of directors on the date of grant (the &#147;Grant Date&#148;). The Equity Awards shall vest and become exercisable in equal annual
installments on the first, second, third, fourth and fifth anniversaries of the Grant Date, respectively, and the Equity Awards shall be further subject to the terms and conditions set forth in the Plan and the Company&#146;s associated Incentive
Stock Option Agreement and Restricted Stock Unit Award Agreements. In addition, you will be eligible to receive additional incentive equity awards under the Company&#146;s executive incentive plans or programs (such plan or program, an &#147;LTI
Plan&#148;). The Company will target the value of any such awards at an aggregate value of 50% of your total target compensation (presently estimated to be $240,000) in 2015. Any actual awards under a LTI Plan (&#147;LTI Awards&#148;) are
discretionary and will be subject to the Company&#146;s assessment of your performance, as well as business conditions at the Company. Any LTI Awards will be subject to approval by and adjustment at the discretion of the Company&#146;s board of
directors or compensation committee and the terms of any applicable LTI Plan. As with the Bonus, the Company expects to review your job </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
performance on an annual basis and will discuss with you the criteria which the Company will use to assess your performance for LTI Plan purposes. The Company also may make adjustments in the
targeted amount of any LTI Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <B>Benefits</B>. You will be eligible to participate in the employee benefits and insurance programs generally made
available to the Company&#146;s full-time employees which currently include health, life, short and long-term disability and a 401(k) plan. Details of these benefits programs, including mandatory employee contributions, and, if applicable, waiting
periods, will be made available to you when you start. You will also be eligible for up to 20 days of Paid Time Off per year (vacation/personal time) which shall accrue on a prorated basis, in accordance with the Company&#146;s vacation policy as in
effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <B>Relocation. </B>The Company will provide you with up to $75,000 to be used in connection with your relocation of your
principal residence from New Jersey to Massachusetts (&#147;Relocation Amount&#148;). Acceptable uses of the Relocation Amount include moving expenses and other reasonable move-related items (collectively &#147;Relocation Expenses&#148;), or other
documented associated with buying or selling your home. Appropriate supporting documentation (i.e., itemized receipts) of the Relocation Expenses must be submitted within 45&nbsp;days after the Relocation Expenses were incurred and prior to
reimbursement. The Company will determine in its reasonable judgment what, if any, of your reimbursed Relocation Expenses are for nondeductible expenses in accordance with applicable law and will comply with associated withholding and tax reporting
obligations. In the event that, at any time within 12&nbsp;months from your Start Date, you resign or you are terminated by the Company for Cause you agree to reimburse the Company for the portion of the Relocation Amount paid to you under this
provision.&nbsp;In the event that, at any time after 12 months but before 24 months from your Start Date, you resign or you are terminated by the Company for Cause you agree to reimburse the Company for fifty percent (50%)&nbsp;of the Relocation
Amount paid to you under this provision.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <B>At-will Employment, Severance</B>. Your employment is &#147;at will,&#148; meaning you or the Company may
terminate it at any time for any or no reason at which time you will be entitled to Accrued Obligations, defined as (1)&nbsp;the portion of your Base Salary that has accrued prior to any termination of your employment with the Company and has not
yet been paid, (2)&nbsp;an amount equal to the value of your accrued unused vacation days and (3)&nbsp;the amount of any expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed and to no other
compensation, <I>provided, however</I>, in the event the Company terminates your employment without Cause (as defined below), in addition to the Accrued Obligations, the Company shall provide to you the following termination benefits (the
&#147;Termination Benefits&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) continuation of your base salary for a period of 6 months at the rate then in effect in accordance
with the terms of the Company&#146;s standard payroll schedule (solely for purposes of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended, each payment is considered a separate payment (&#147;Salary Continuation Payments&#148;)); and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) continuation of group health plan benefits for a period of 6 months to the extent authorized by and consistent with 29 U.S.C. &#167;
1161 et seq. (commonly known as &#147;COBRA&#148;), with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and you as in effect on the date of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) full vesting of 50% of the then unvested Equity Awards, provided that you shall have with 90 days from such termination to exercise the
Option Grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary in this Agreement, you shall not be entitled to any Termination Benefits unless you first
(i)&nbsp;enter into, do not revoke, and comply with the terms of a separation agreement in a form acceptable to the Company which shall include a release in favor of the Company and related persons and entities (the &#147;Release&#148;);
(ii)&nbsp;resign from any and all positions, including, without implication of limitation, as a director, trustee, and officer, that you then hold with the Company and any affiliate of the Company; and (iii)&nbsp;return all Company property and
comply with any instructions related to deleting and purging duplicates of such Company property. The Salary Continuation Payments shall commence within 60 days after the date of termination; <I>provided, however</I>, that if the 60-day period
begins in one calendar year and ends in a second calendar year, the Salary Continuation Payments shall begin to be paid in the second calendar year. All compensation and benefits payable to you, other than the Termination Benefits, shall terminate
on the date of termination of your employment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <B>Representation Regarding Other Obligations</B>. This offer is conditioned on your representation that your
employment by and rendering of services to Repligen Corporation as its Chief Financial Officer shall not constitute a violation of any noncompete agreement between you and any other organization, including Maquet Cardiovascular LLC. If you have
entered into any agreement that may restrict your activities on behalf of the Company, please provide the CEO with a copy of such agreement as soon as possible. You also represent that you have not violated, and covenant that you will not violate,
any other obligation to any previous employer or any other party, including that you have not used and will not use or disclose any trade secret or other proprietary right of any previous employer or any other party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <B>Definitions</B>. For purposes of this Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Cause&#148; means (i)&nbsp;conduct constituting a material act of misconduct in connection with the performance of your duties, including, without
limitation, misappropriation of funds or property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of Company property for personal purposes; (ii)&nbsp;the commission of any felony or a
misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&nbsp;non-performance of your duties hereunder (other than by reason of your physical or mental illness, incapacity or disability) or repeated violations of your material
responsibilities and material duties as determined in good faith by the Company and which has continued for more than 30 days following written notice which notice shall specify in reasonable detail the performance problems and the actions required
to cure such performance problems; (iv)&nbsp;a breach by you of any of the material provisions contained in any other written agreement by and between you and the Company that, if cureable, is not cured within thirty (30)&nbsp;days after the Company
notifies you in writing that it believes you have materially breached your obligations under this Agreement, which notice shall specify in reasonable detail such breach and the actions required to cure such breach; (v)&nbsp;a material violation of
any of the Company&#146;s written employment policies as applied to other employees in the Company which has continued for more than 30 days following written notice which notice shall specify in reasonable detail such violation and the actions
required to cure such violation; or (vi)&nbsp;failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful
destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <B>Taxes; Section&nbsp;409A</B>. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and
payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company
or its board of directors related to tax liabilities arising from your compensation. Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section&nbsp;409A of the Code, the
Company determines that you are a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement on account of your
separation from service would be considered deferred compensation subject to the 20 percent additional tax imposed pursuant to Section&nbsp;409A(a) of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment
shall not be payable and such benefit shall not be provided until the date that is the earlier of (A)&nbsp;six months and one day after your separation from service, or (B)&nbsp;your death. If any such delayed cash payment is otherwise payable on an
installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in
accordance with their original schedule. All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All
reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits
provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to reimbursement or in-kind benefits is not subject
to liquidation or exchange for another benefit. To the extent that any payment or benefit described in this Agreement constitutes &#147;non-qualified deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such
payment or benefit is payable upon your termination of employment, then such payments or benefits shall be payable only upon your &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall
be made in accordance with the presumptions set forth in Treasury Regulation Section&nbsp;1.409A-l(h). The Company and you intend that this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement will be administered in accordance with Section&nbsp;409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the
Code, the provision shall be read in such a manner so that all payments hereunder comply with Section&nbsp;409A of the Code. The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of
this Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <B>Interpretation, Amendment and Enforcement</B>. This Agreement and the Equity Documents, as modified herein, constitute the complete agreement between
you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. The terms of this Agreement and
the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with, this Agreement, your employment with the Company or any other relationship between you
and the Company (the &#147;Disputes&#148;) will be governed by Massachusetts law, excluding laws relating to conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the
Commonwealth of Massachusetts in connection with any Dispute or any claim related to any Dispute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <B>Successors and Assigns</B>. This Agreement shall
be binding upon and inure to the benefit of both parties and their respective successors and assigns, including any corporation with which or into which the Company may be merged or which may succeed to its assets or business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <B>Other Terms</B>. Your employment with the Company will be on an &#147;at will&#148; basis. In other words, you or the Company may terminate your
employment for any reason and at any time, with or without cause. Although your job duties, title, compensation and benefits, as well as the Company&#146;s benefit plans and personnel policies and procedures, may change from time to time, the
&#147;at will&#148; nature of your employment may only be changed in an express written agreement signed by you and the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, this offer
is subject to satisfactory background and reference checks. As with all employees, our offer to you is also contingent on your submission of satisfactory proof of your identity and your legal authorization to work in the United States. You also will
be required to sign, as a condition of your employment, the Company&#146;s standard form of restrictive covenant agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are excited about the
prospect of having you join the Company. We look forward to receiving a response from you within one week acknowledging, by signing below, that you have accepted this Agreement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Walter C. Herlihy</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Walter C. Herlihy</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I have read and accept this employment offer: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jon Snodgres</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Jon Snodgres</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">June 10, 2014</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d757843dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="6">


<IMG SRC="g757843ex99_1logo.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Repligen Corporation</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">41 Seyon Street</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Building #1, Suite 100</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Waltham, Massachusetts 02453</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Telephone: (781) 250-0111</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Telefax: (781) 250-0115</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Repligen Hires Jon K. Snodgres as Chief Financial Officer </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WALTHAM, MA &#150; July&nbsp;15, 2014 </B>&#150; Repligen Corporation today announced that Jon K. Snodgres has been named its Chief Financial Officer.
Mr.&nbsp;Snodgres joins Repligen from his CFO role at Maquet Cardiovascular, a medical device company. Over the course of five years with Maquet, Mr.&nbsp;Snodgres contributed to the company&#146;s growth from niche status to a diversified business
generating over $1 billion in annual revenue. Mr.&nbsp;Snodgres previously spent eight years with life sciences company Thermo Fisher Scientific where he was Vice President of Finance for the Laboratory Products Group. At both Maquet and Thermo
Fisher, Mr.&nbsp;Snodgres held key responsibility for numerous acquisitions and restructuring programs. He was also integral to the success of pricing and facility optimization programs that drove substantial earnings improvements.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I would like to welcome Jon to the Repligen management team,&#148; said Walter C. Herlihy, President and Chief Executive Officer of Repligen. &#147;We
look forward to drawing on his rich experience with growth-driven life sciences companies as we expand our organization to build a best-in-class bioprocessing company.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Snodgres joined Maquet Cardiovascular as CFO in 2009. There, in addition to P&amp;L, balance sheet and cash flow responsibility, he was a key
participant in growth planning and profit improvement strategies. During his tenure with Maquet, the company&#146;s cardiovascular business significantly increased sales and earnings through acquisitions, organic growth, portfolio management,
pricing discipline and restructuring actions. While with Thermo Fisher Scientific, as Laboratory Products Group Vice President of Finance from 2005 to 2008, Mr.&nbsp;Snodgres helped drive profit improvements through acquisition, consolidation and
facility optimization, as well as the implementation of analytical tools and processes that enhanced decision making. Mr.&nbsp;Snodgres has also served as Vice President of Financial Operations for Newport Corporation, a laser and photonics
solutions provider. He began his career in finance at AlliedSignal/Honeywell International. Mr.&nbsp;Snodgres received a Bachelor of Science degree in Business Administration, Finance from Northern Arizona University. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Repligen Corporation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repligen Corporation
(NASDAQ:RGEN) is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of Protein A media that is used to separate and purify
monoclonal antibody therapeutics. Our line of ATF (Alternating Tangential Flow) filtration devices and our growth factor products are used to increase product yield during the fermentation stage of biologic drug manufacturing. In addition, we
develop and market an innovative line of &#147;ready-to-use&#148; chromatography columns under our OPUS<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> brand (Open Platform User Specified) that we deliver pre-packed to our
biopharmaceutical customers with their choice of purification media. Repligen&#146;s corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA and Lund, Sweden. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section&nbsp;27A of the Securities Act of
1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that express or implied statements in this press release which are not strictly historical statements, including, without limitation,
statements identified by words like &#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;seek,&#148; or &#147;could&#148; and similar expressions and any other statements regarding the expansion of
our commercial organization and opportunities to grow our bioprocessing business or our product portfolio or the general future potential of our business constitute forward-looking statements. Such forward-looking statements are subject to a number
of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks detailed in Repligen&#146;s annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports
that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These forward looking statements reflect management&#146;s
current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repligen Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sondra Newman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(781) 419-1881 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>snewman@repligen.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source: Repligen Corporation </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g757843ex99_1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g757843ex99_1logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`'P!^`P$1``(1`0,1`?_$`',```(!!0$!`0``````
M``````D*"``!`@4'`P0&`0$`````````````````````$```!@(!!`$#`P,"
M!P`````"`P0%!@<!"`D`$1(3"B$4%3$B%D%1(V$R@<'10I(D&!$!````````
M`````````````/_:``P#`0`"$0,1`#\`9GYW^12>\8?'G-MD:B3PY;<:RP:T
MK6KT4^:5S[%%#[*I"%<_B=&AL>6!<L^UK]A>3B,`5%X"I++$+`@XR'(+BTKR
MB?+:V)JF"7A36A^O,VJRS8^EE4$EI$,C;.GD4=79,PA=DK=(MG6AY(2K`EY&
M5D],5DPO.!AQD`@YR$KN&;Y%&V&SF^KKQI\BFO\`!ZNOHY19+!'GZOF22PY>
MQV)5C4\R:3U]8<+D,DEZ;N;'H^X#2.:!805@U(67DDX"G"@L'&C32B2S#CC"
MRBB@"&:::,)998`8\A#,&+.`@`$..^<YSVQCH,@B",(1@$$0!!P((@YP((@B
MQW"((L=\9#G&?IGH+]!XDJ$ZCV^@\D_T'#3G^DT!GI/+[>PDWP$+UG`[X[AS
MVSC^N.@5L^0CS+;7\=5W:1ZX:6M%1O\`:FRILG-DZ&T(B]S(PA,X2V%P2KR6
M-`Q2R,'I1ODC7O`#!&8.]N4@0EXQD(NX3'Y59GS:,\_U<A?%S$JD<XRYH'4.
MS%F6$JIS)38YN;U$VF/&L,-L2?Q^2F)&5O3/#@>6VIU@E05!1`!Y-*\<A+KD
MDY)Z5XR:';K.M1,]6)9$Y>$\!H2AX.5[;+O^U5N$J=OB41;4Z9Q-1I/NUI`G
M%P^W/*0%'%@`6H5GI$BD!9,<:^4/LE'T]QBN/0K0;#LF`]1'5UPK9XN"2HT!
MA0SF]BN.>N++-B6=Z4`$7A4-B4F"*R+/=.F-"(C`=0XB.4W:J_-E=G>-KD?J
M2#53O3JPT(9P>\5<8I)KJW*K<E3"E(E;(W+W1X,3*22Y:S+2E"91E,XH'<L7
MVJ$Y,>3D&%>@KO\`]>@KH*Z!$#YN=ZG`K_1/51F/,5K)?.;*O"0,Z3R-5YS$
M6AFKR`C^U)'DXW\FIG;\`H/K%YF)LX#GOC..@T]7_*5D.F&G]/TZQ\0^R;.R
M:_4Q6M3-<IL>:/$)A8PP6)L\2(>7MS%1ZG[(+HH;O>(OO@0S#<A\\9SWZ#GO
M`U%(C/IUOY\F+;FT:X?W^O2-C9:;2%:8<RWJKI2Y1XZ12E4^)WP@@MM5N%>*
M<,,.0E*G,*U,ZB-4*<*B\`"`V(!M'3W-I;MXWIS'\L$FTOJIK?3&*AM4*MS*
MS&EO:UZ)2J"H:FPN+R>&H(]&TBA*C4N2]`M?I*JRHR<>E`27D8$1^+)M'8=;
M\FNVV@L'V;?]E]'F6NK<G593"0*'\,=]%6V+$66'VE$6>1&*3Z^33.(RDX+N
M@*RG3*#Q$#,\QIB19"*'%/K+M/S:\CG)!=L3VTN?6C5^33JP5%NS:JI$O(G<
MD@]U6@^2B#T?6R]P._'1E*\,D-`<Z+PDFX(;4`$IR<XI>(H8?965)W%P8?)&
MUKU*UWV)L.TZKO6>46U2YHD3NGPX3.L;]=C(M(H_;+"A6H(LYR^)+B53LW.'
MI3F`]*)8`LL0Q%""9^X?;>_YB>L]0`Q^5BFHQU/!7!48^Z;2`T7!GW:YXQE/
M_D++P9.)$!N'Y8QW/#C`OTQT'M-5"C>KYET48$IY[M`=/SV+"KR.,RE;?_G>
MGE,V48^W\L`QA)L#*<)NWUQDP?E]?TZ`CU9EE\AORE;S?IWY2"H.(^@V6.4[
M'%I1)[(@O.?$1[#I*C&\W&2A/*5WE+\,I7D.3@*(ZV##G&4Q0L`9;D`Y';'T
MEE]?1.`<>6ZFZP9K&W60NTBU>K95,8Y!1(7,MM1,LF<P)SB"'MVQ@T\LC&<#
M`07@8OH,/00.T"Y4-2-O-H]U[?DO'U.M.M@].=?BEVSUZ7M"(*RV^PUNFR8_
M%5K)ES40.?ITB9EA)[IA`KR$D)36'L#RP#L`<JKV'U3YJ7"?;1\HG+)'-1J!
M=)I*XQJ]QS5WN'7=!+XI6L<<LM+59&Q!2A]&_2.PY4J2'*"RE"<KUA"%0F."
M@4$(R@EQP*VTQTIR9[_\>6O^XK]NOH)":0@.QE"VA(+4:KB05DY&*(.R2N`M
MT\8AJ(^,G(YN:G4DI!IDO>/`.PE*4F+,B"/O$GJ???,H1O[LOL%M_L]7.CUX
M;IV^NK^F*3LMS@3_`&N2WN:@YM12J;*?SKTQTA7C#("$#;&&G"-*X.XE9RH7
MBB3@&&FTLTC:W?=_F6X:#]L=FI!QVP]MTZ<25SM8RA;/:\M"0W'2-FME?1&6
M+B3T3"NEZE.[1-Q6H$9`UZ,HL9Y0U2<(N@Y-RD5S8F^'RJ-/*=%`)D[4YKT\
MZVQI^D!L3D&(*H9H0%?M58@#I`<W"8C0K43X-J-&$W`3#R0I_+SQCH&K><65
MO</XC]_%T<B[G,GU^UXEE=M<>9V(<E<52NUCF^L"U:9E+2KAK/P_\O\`O1]B
MAY*`G$9V_9WP"K'"[Q]VM='QM.2ZF($WN[-L5LA94]+8X7($KG%78Y16$1J5
M\A\&5IWT#06W'V$8T+4I2DS.$F2W8O)QOK`,(`&YQV;QT#HGK2_Z6[9<#I^S
M&\,0EL^,KMTG>L<-?)7+CY"YC4,\<LD,WKEXLY*1%G\XU&4)L3N@#T`2BB0$
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MKYM$I`PY+)O6XE3['LM`WMN(PH,CU7UNI1#`0+R*(4@#VP`?CD-E\6.L+,O'
MDVY1^1"V(!,HDKF0G\B.'3B*R"/G*EVR=T/MH.I;*8_H$@U&6%HKA,F."`0A
MDE*R@CQC`\=P[Y=%B6#P0\XNU.Z]PTS;-E<>G(O$(J<_W%5L1.FBVGK2:P-`
M\M\H*(RD+38;)$WNHL(!FDF+F5Y3GHQ*U2`])T!(G/Y&NMM^LI\)XNZ=V$Y`
M=DY&##1"(3%*4LJNJMB[\O":4AD%VVM8T?B;'!8"T&@R<N5@$=D0`>OS)P+)
MY0"]XLM%MQ+GXRN?%5;9!H-X=W+IV<J=<[*RL,#7/9A7D-=FX`8\ZN[8E2@K
M^6V-/'UK;U999:(I"+&21E8!Y%A'C0;=7AXU]U-J/5S=+B-DCOR#4K%!UG8E
M5K>.:(V?;=LS6-JE*1"^M\B>8D4N=G"7I<DF#$[&ISBE'M#@1Q023SP+I"F^
MW-:.);D&W1F_'SJOHI>%ATG;:77ZC-4:"11&\H97DL9CX[2\<V"?8JARKE5H
M"F3^B7+DJ-`@2M99(#%"5.I^Y3)`(9P1:\J-5^(S2*M7MJ4,$@54TCM>8('$
M@U&YH)%<[HZVXZ(WE.J*(4)'%G!,`(SB30A,3Y3>L6.X.@74T]E5I030;EOY
M572"68AF]_\`,%K#;+$PJ8=)BIL\Z_TKO=KG(T*)OBYB'#\H:2XM-Y`W"`67
MG&4R0P.<^)><X!Z'H+?3OC^_U[?\^@OT&/[?+'^WS\<]OT\O'OCOV_KX]^W0
M`.^2?1]M[&<7TWJ&L+"H>IV:2VI4RJW;%V/N*.T;5\<K=@D(WU*!?/)5@+(F
M<WJS$,<1)DYQA6%`C\@"+(\A`,)6\+-00.A.+G3>HX!8U16TUPRK\))#85&3
MV.6?5<BLEPDKZ]6D.)3Z+'J&23I&VR7)S1B4%"\O<G$`>`C#D.`*-T%=!;Z=
M\?W_`*=!@=Z?49]QZO1X"]ON\?5Z^W[O9Y_L\.WZ]_IVZ#0QC^)_B@?PS^/?
MA/:=Z_XQ^-_%>_R_S^'XK_U/=Y_[^W[N_P"O0?HN@P_Q^S_L]OA_I[/7W_\`
4+P\O^'?H,^@K/;^OZ?Z]!70?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
